APA (7th ed.) Citation

Cheung, L., Cruickshank, M. N., Hughes, A. M., Singh, S., Chua, G., Ford, J., . . . Kotecha, R. S. (2019). Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

Chicago Style (17th ed.) Citation

Cheung, Laurence, et al. Romidepsin Enhances the Efficacy of Cytarabine in Vivo, Revealing Histone Deacetylase Inhibition as a Promising Therapeutic Strategy for KMT2A-rearranged Infant Acute Lymphoblastic Leukemia. 2019.

MLA (9th ed.) Citation

Cheung, Laurence, et al. Romidepsin Enhances the Efficacy of Cytarabine in Vivo, Revealing Histone Deacetylase Inhibition as a Promising Therapeutic Strategy for KMT2A-rearranged Infant Acute Lymphoblastic Leukemia. 2019.